Letter by Koh Regarding Article, “Effect of Omega-3 Acid Ethyl Esters on Left Ventricular Remodeling After Acute Myocardial Infarction: The OMEGA-REMODEL Randomized Clinical Trial”
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
Heydari et al1 reported that high-dose 4-g omega-3 fatty acids containing ethyl esters of eicosapentaenoic acid (≈1860 mg) and docosahexaenoic acid (≈1500 mg) for 6 months significantly reduced left ventricular systolic volume index and noninfarct myocardial fibrosis, but did not reduce high-sensitivity C-reactive protein and triglycerides in comparison with placebo.
Atherosclerosis is associated with multiple mechanisms that include endothelial dysfunction with impaired nitric oxide bioavailability, oxidative stress, inflammation, hemostasis, and insulin resistance. Cardiovascular events were significantly reduced with hydroxymethylglutaryl-coenzyme A reductase inhibitors (statin) therapy through reduction of low-density lipoprotein cholesterol …